| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| B303060-1mg |
1mg |
现货  |
| |
| B303060-5mg |
5mg |
现货 |
|
| 产品名称 | Bevacizumab (anti-VEGF) |
|---|---|
| 别名 | 贝伐单抗 |
| 英文别名 | Anti-Human VEGF | Humanized Antibody | rhuMab VEGF, Avastin |
| 规格或纯度 | Moligand™, ≥95%, ~25mg/ml(in buffer,PH6.2 |
| 克隆类型 | 重组抗体 |
|---|---|
| 浓度 | ~25mg/ml(in buffer,PH6.2 |
| 储存温度 | 避光,-20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| CAS编号和信息 | 216974-75-3 |
| 分子类型 | 抗体 |
| Appearance(B303060) | Colorless to white to light yellow Liquid |
|---|---|
| Purity(HPLC) | 95-100（%） |
| ICP: Confirms Lithium Component | Confirmed |
| Proton NMR spectrum | Conforms to Structure |
| Bacterial endotoxins | 0-3（EU/ml） |
| Concentration | 22.5-27.5（mg/ml） |
| 1. Wenjuan Huang, Liwen Wang, Ruhui Yang, Ronggui Hu, Qinxiang Zheng, Xingjie Zan. (2022) Combined delivery of small molecule and protein drugs as synergistic therapeutics for treating corneal neovascularization by a one-pot coassembly strategy. Materials Today Bio, 17 (100456). [PMID:36281304] [10.1016/j.mtbio.2022.100456] |
| 1. Wenjuan Huang, Liwen Wang, Ruhui Yang, Ronggui Hu, Qinxiang Zheng, Xingjie Zan. (2022) Combined delivery of small molecule and protein drugs as synergistic therapeutics for treating corneal neovascularization by a one-pot coassembly strategy. Materials Today Bio, 17 (100456). [PMID:36281304] [10.1016/j.mtbio.2022.100456] |
首页
400-620-6333
G2207118